US FDA expands use of Novartis drug for chronic skin condition

The US FDA has expanded the approved use of Novartis' drug remibrutinib (Rhapsido) to treat symptomatic dermographism in adults, a chronic skin condition with itchy welts triggered by scratching or friction. This approval follows positive late-stage trial results showing significant symptom resolution and expands remibrutinib's treatment scope beyond chronic spontaneous urticaria.

This Wire brief sits within Fusion42's coverage of Health, and 7 sources have reported it between 7 Oct 2026 and 10 Oct 2026.